BiotechTube

iSONEP (sonepcizumab/LT1009)

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pigment Epithelial Detachment

Conditions

Pigment Epithelial Detachment

Trial Timeline

Mar 1, 2011 → Jul 1, 2012

NCT ID
NCT01334255

About iSONEP (sonepcizumab/LT1009)

iSONEP (sonepcizumab/LT1009) is a phase 1 stage product being developed by Pfizer for Pigment Epithelial Detachment. The current trial status is terminated. This product is registered under clinical trial identifier NCT01334255. Target conditions include Pigment Epithelial Detachment.

What happened to similar drugs?

3 of 4 similar drugs in Pigment Epithelial Detachment were approved

Approved (3) Terminated (1) Active (1)
🔄Pexidartinib + PlaceboDaiichi SankyoPhase 3
✅intravitreal injection with ranibizumabNovartisApproved
✅AfliberceptRegeneron PharmaceuticalsApproved
✅AfliberceptRegeneron PharmaceuticalsApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01334255Phase 1Terminated

Competing Products

20 competing products in Pigment Epithelial Detachment

See all competitors
ProductCompanyStageHype Score
Pexidartinib + PlaceboDaiichi SankyoPhase 3
40
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
39
AGN-151597AbbViePhase 1/2
32
nilotinibNovartisPhase 2
35
intravitreal injection with ranibizumabNovartisApproved
43
MCS110 + PlaceboNovartisPhase 2
35
CPK850NovartisPhase 1/2
36
RanibizumabNovartisPhase 2
35
AfliberceptRegeneron PharmaceuticalsApproved
35
AfliberceptRegeneron PharmaceuticalsApproved
43
BIIB112BiogenPhase 1/2
29
OCU400OcugenPre-clinical
24
OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye DosingOcugenPhase 1/2
30
4D-125 IVT Injection4D Molecular TherapeuticsPhase 1/2
30
AfamelanotideClinuvel PharmaceuticalsPhase 2
25
AfamelanotideClinuvel PharmaceuticalsPhase 2
25
QR-1123ProQRPhase 1/2
26
QR-421aProQRPhase 1/2
22
ADX-2191 + ADX-2191Aldeyra TherapeuticsPhase 2
25
BS01Bionic SightPhase 1/2
29